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Abstract
Heart failure is associated with impairment in nitric oxide (NO) mediated vasodilatation, which has been demonstrated to
result from a reduction in the relative expression of the leucine zipper positive (LZ+) isoform of the myosin targeting subunit
(MYPT1) of myosin light chain phosphatase. Further, captopril preserves normal LZ+ MYPT1 expression, the sensitivity to
cGMP-mediated vasodilatation and modulates the expression of genes in the p42/44 MAPK and p38 MAPK signaling
cascades. This study tests whether angiotensin receptor blockade (ARB) with losartan decreases p42/44 MAPK or p38 MAPK
signaling and preserves LZ+ MYPT1 expression in a rat infarct model of heart failure. In aortic smooth muscle, p42/44 MAPK
activation increases and LZ+ MYPT1 expression falls after LAD ligation. Losartan treatment decreases the activation of p42/
44 MAPK to the uninfarcted control level and preserves normal LZ+ MYPT1 expression. The expression and activation of p38
MAPK, however, is low and does not change following LAD ligation or with losartan therapy. These data suggest that either
reducing or blocking the effects of circulating angiotensin II, both decreases the activation of the p42/44 MAPK signaling
cascade and preserves LZ+ MYPT1 expression. Thus, the ability of ACE-inhibitors and ARBs to modulate the vascular
phenotype, to preserve normal flow mediated vasodilatation may explain the beneficial effects of these drugs compared to
other forms of afterload reduction in the treatment of heart failure.
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Introduction
Activation of smooth muscle is dependent on the level of
phosphorylation of the 20 kDa regulatory myosin light chain
(MLC20), which is determined by the relative activities of MLC
kinase (MLCK) and MLC phosphatase [1,2]. Until recently,
activation and relaxation of smooth muscle were thought to be
regulated by MLCK, while MLC phosphatase was an unregulated
housekeeping enzyme [3]. However, evidence indicates that the
majority of signaling pathways for the regulation of vascular tone
converge on MLC phosphatase [4,5].
MLC phosphatase isolated from smooth muscle is a holoenzyme
consisting of three subunits [4]; a 20 kDa subunit of unknown
function, a 38 kDa catalytic subunit and a myosin targeting
subunit (MYPT1) of 110–133 kDa. Alternative splicing of two
different exons generates four MYPT1 isoforms. One exon codes
for the presence or absence of a 41 aa central insert [5]. The other
is a 31 bp 39 exon; exon inclusion codes for a MYPT1 that lacks a
COOH-terminus leucine zipper (LZ2), while exon exclusion shifts
the reading frame and codes for a LZ+ MYPT1 isoform [6].
Nitric oxide (NO) is the classical agent to produce Ca
2+
desensitization [7], and NO-mediated, or flow-mediated, vasodi-
latation is a fundamental response of the vasculature [8]. In the
vasculature, an increase in flow increases shear stress on
endothelial cells, which stimulates NO production. NO diffuses
into the smooth muscle cells to activate the soluble pool of
guanylate cyclase, to increase cGMP, which then activates type I
cGMP-dependent protein kinase (PKGI), which subsequently
produces smooth muscle relaxation by its interactions with the
maxi K
+ channel [9], the SR and voltage dependent Ca
2+
channels [10,11] and MLC phosphatase [12]. In addition, PKGI
dependent pathways for vasodilatation include a phosphorylation
of telokin [13,14,15] and HSP20 [16].
A number of groups have demonstrated that the sensitivity to
cGMP-mediated smooth muscle cell relaxation correlates with the
relative expression of LZ+/LZ2 MYPT1 isoforms
[6,17,18,19,20], suggesting that the relative expression of LZ+/
LZ- MYPT1 isoforms could determine the sensitivity of the
smooth muscle to NO mediated vasodilatation [12]. However, not
only does the relative expression of LZ+/LZ2 MYPT1 isoforms
correlate with the sensitivity of cGMP-mediated relaxation; we
have demonstrated that changes in LZ+/LZ2 MYPT1 expres-
sion, in isolation, cause changes in the sensitivity to cGMP-
mediated smooth muscle relaxation [21].
We have previously demonstrated that between 2–4 weeks
following a myocardial infarction, the expression of the LZ+
MYPT1 isoform decreases and this is accompanied by a decrease
in the sensitivity to NO mediated vasodilatation [22]. Further
captopril therapy preserves both normal LZ+ MYPT1 expression
and sensitivity to NO mediated vasodilatation [22] as well as
suppresses the expression of genes involved in p42/44 MAPK and
p38 MAPK signaling [23]. The present study examined whether
captopril treatment of heart failure maintains LZ+ MYPT1
expression by decreasing angiotensin II (Ang II) by testing the
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LZ+ MYPT1 expression and decrease the activation of either
p42/44 or p38 MAPK.
Results
Left Ventricular Function
The uninfarcted control rats had normal cardiac function with
LVEF averaging 7161% (n=9). Following LAD ligation, left
ventricular function was significantly reduced with an LVEF of
4361% (n=12, p,0.05, Fig 1). Losartan therapy, following LAD
ligation, did not improve LVEF compared to vehicle treatment
(4363%, n=9). Compared to vehicle treatment post infarction,
the heart rate was significantly higher in the losartan treated rats
(30466 bpm vs 32868 bpm, p,0.05). Post LAD ligation LVESD
(0.1560.01 cm vs 0.1760.02 cm) and LVEDD (0.8260.05 cm vs
0.8660.04 cm) were slightly larger in the losartan compared to
vehicle therapy group, but these differences were not significant
(p.0.05).
MAPK Signaling
In control rats, as well as in the animals post-LAD ligation, both
with and without losartan therapy, p42/44 MAPK, and the
activated form of p42/44 MAPK (phospho-p42/44 MAPK) were
easily detected (Fig 2). Total p42/44 MAPK expression,
normalized to actin, did not change following LAD ligation or
with treatment (p.0.05). Four weeks following LAD ligation,
there was a significant (p,0.05) activation, or phosphorylation, of
p42/44 MAPK in the vehicle treated animals (Fig 2). Compared
to vehicle treated rats, losartan therapy following LAD ligation
resulted in a significant reduction in the level of activation of p42/
44 MAPK (p,0.05), and the relative level of phosphorylation of
p42/44 MAPK was not different than that in the uninfarcted
control animals (p.0.05, Fig 3).
In contrast to p42/44 MAPK, the expression of p38 MAPK was
low; i.e., barely detectable (Fig 3). Similar to total p38 MAPK
expression, phospho-p38 MAPK expression was also difficult to
detect. There was no change in the intensity of p38 MAPK and
phospho-p38 MAPK in control rats or rats following LAD ligation
(Fig 3). Due to the low levels of p38 expression, we do not feel that
the calculation of relative phosphorylation of p38 MAPK is
reliable.
To determine the effect of ARB therapy on MAPK signaling in
normal animals, we treated uninfarcted control rats with losartan
for four weeks. In control animals, losartan decreased the
phosphorylation of p42/44 MAPK compared to vehicle treated
animals (1.060.2, n=9 vs. 0.560.3, n=4, p,0.05, Fig 2).
However, p38 MAPK expression and activation remained low/
undectable in uninfarcted animals treated with losartan.
MYPT1 Expression
To determine if LZ+ MYPT1 expression was modulated in
heart failure, we used Western blotting with two different
antibodies, one of which recognized all MYPT1 isoforms and an
anti-LZ+ MYPT1 antibody. Following LAD ligation, consistent
with our previous results [22,24], the relative expression of the
LZ+ MYPT1 isoform decreased (p,0.05, Fig 4). However in the
losartan treatment group, MYPT1 LZ+ isoform expression
remained at control levels (Fig 4). Treatment of control,
uninfarcted rats with losartan for 4 weeks did not change the
relative expression of the LZ+ MYPT1 isoform (Fig 4, p.0.05). In
aortic smooth muscle of normal rats, we have demonstrated that
the MYPT1 transcript is 9466% LZ+ and the expression of
MYPT1 is nearly exclusively LZ+ [24,25]. Thus, it is unlikely that
losartan treatment would produce a significant increase in LZ+
MYPT1 expression in the normal rat aorta.
Discussion
Both ACE-inhibition and ARB therapy post myocardial
infarction have been demonstrated in both animals
[26,27,28,29,30] and humans [31,32] to prolong survival. In our
study, LAD ligation produced a moderate reduction in LVEF
(LVEF,40%, Fig 1) and losartan did not improve LVEF. These
results are consistent with those of Pourdjabber et al. [33]. These
investigators demonstrated that both low (3 mg/kg/day) and high
(30 mg/kg/day) dose losartan therapy improved post-MI survival.
However, the effect on LV function was dependent on infarct size;
for large infarcts (LVEF,10%) both high and low dose losartan
treatment improved LV function, whereas neither dose, similar to
our results, improved LVEF for moderate (LVEF,30%) sized
infarcts.
During cGMP stimulation, several groups have demonstrated
that MYPT1 is phosphorylated at Ser695 [34,35]. However, there
is ample experimental evidence that demonstrates a Ser695
phosphorylation of MYPT1 cannot be the sole mechanism by
which cGMP stimulation mediates MLC20 dephosphorylation
[36]. MYPT1 phosphorylation at Ser695 does not increase MLC
phosphatase activity [35], but rather decreases the level of Thr696
phosphorylation to disinhibit the MLC phosphatase and return
phosphatase activity to baseline levels [34,35]. Ca
2+ desensitization
(MLC20 dephosphorylation at a constant [Ca
2+]) occurs during all
types of smooth muscle activation, including those that MYPT1 is
not phosphorylated at Thr696 [36,37,38,39]. These results
contrast with those for the relationship between LZ+ MYPT1
and sensitivity to cGMP; results consistently demonstrate that LZ+
MYPT1 expression determines the sensitivity to cGMP-mediated
vasodilatation [13,18–20,23,26].
Mendelsoln’s group [40] has demonstrated the importance of
PKGIa-MYPT1 signaling for vascular function. These investiga-
tors generated transgenic mice expressing a mutant PKGIa that
was unable to interact with MYPT1, and compared to WT
controls, the transgenic mice were both hypertensive and the
vascular smooth muscle was less sensitive to both ACh and cGMP
mediated vasodilatation. These results demonstrate that normal
sensitivity to NO mediated and/or flow mediated vasodilatation is
required for the maintenance of normal vascular resistance and
blood pressure. Thus a decrease in LZ+ MYPT1 expression would
decrease PKGIa-MYPT1 signaling and result in a decrease in
Figure 1. Left ventricular function is reduced in rats following
LAD ligation. Bar graph for LVEF (mean6SEM) in uninfarcted, control
rats (n=9), as well as rats 4 weeks following LAD ligation treated with
vehicle (CHF, n=12) or losartan (CHF+losaratan, n=9). The * indicates a
significant difference (p,0.05) compared to control.
doi:10.1371/journal.pone.0005144.g001
MAPK Signaling during CHF
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that changes only in LZ+ MYPT1 expression cause changes in the
sensitivity to cGMP [21], and a number of groups have
demonstrated that the relative expression of the LZ+ MYPT1
isoform determines the sensitivity to cGMP mediated smooth
muscle cells relaxation in normal animals, during development
and in disease states [13,18–20,23,26].
The results of the present study demonstrate that losartan therapy
following an MI maintains MYPT1 LZ+ expression at baseline
control levels (Fig 4). These results suggest that the ability of ACE-
Figure 2. There is a significant activation of p42/44 MAPK following LAD ligation, which is preserved with ARB. (A) Western blots
demonstrate that while the expression of p42/44 MAPK does not change following LAD ligation, there is a significant increase in the phosphorylation
(activation) of p42/44 MAPK following LAD ligation in the animals treated with vehicle (CHF), which returns to control levels with losartan therapy
(CHF+losartan). In addition, treatment of control animals with losartan decreased the activation of p42/44 MAPK. The Coomassie stained gel shows
actin, the loading control. (B) Bar graph represents the relative phosphorylation of p42/44 MAPK in control and animals after LAD ligation. The relative
phosphorylation of p42/44 MAPK in the controls was set at 1, and the data represent mean6SEM for control (n=9), and rats following LAD ligation
treated with vehicle (CHF, n=12) or losartan (CHF+losartan, n=9), as well as control animal treated with losartan (Control+losartan, n=4). The *
indicates a significant difference compared to controls, while the
‘ is a significant difference compared to losartan treatment.
doi:10.1371/journal.pone.0005144.g002
MAPK Signaling during CHF
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sensitivity tocGMPmediated smoothmusclerelaxation following an
MI [22] is not secondary to a decrease in blood pressure, as LZ+
MYPT1 expression is not preserved with prazosin [22], nor an effect
of bradykinin, but rather due to the ability of the ACE-inhibitor to
decrease Ang II. In heart failure, treatment with an ARB has been
demonstrated to preserve the normal sensitivity to ACh induced
vasodilatation [41]. Post LAD ligation, we have previously
demonstrated that there is no change in the expression of PKGIa
[24]. Thus during the treatment of heart failure, these results are
consistent with both ACE-inhibitor and ARB therapy decreasing
Ang II mediated signaling to alter the vascular phenotype by
preventing the fall in LZ+ MYPT1 expression. The maintenance of
LZ+ MYPT1 expression would preserve the normal sensitivity to
NO mediated vasodilatation.
In animal models of heart failure, activation of MAPK signaling
has been demonstrated in cardiac muscle and treatment with ARBs
reduces the activation of MAPK signaling pathways [42,43].
Additionally, the importance of MAPK signaling for the activation
of hypertrophic pathways in cultured smooth muscle cells has been
well described [44]. However, we are unaware of any data on
MAPK expression and/or activation in vascular smooth muscle
during heartfailure.Nonetheless,our results show that inthenormal
rat, the expression of p38 MAPK is low and does not change
following a LAD ligation or with losartan therapy (Fig 3). Thus
despite the well documented importance of p38 MAPK signaling in
regulating hypertrophy of cultured smooth muscle cells, p38 MAPK
does not appear to be part of a physiologically relevant signaling
pathway in rat aortic smooth muscle. In contrast, p42/44 expression
iseasilydetected(Fig2).FollowingLADligation,thereisasignificant
activation of p42/44 MAPK and losartan decreases the phosphor-
ylation of p42/44 MAPK to control levels (Fig 2). These results show
that treatment with an ARB alters the vascular phenotype to
preserve normal LZ+ expression and decreases the activation of
p42/44 MAPK. Coupled with our previous results [22], which
demonstrated that treatment with the ACE inhibitor, captopril,
preserves normal LZ+ expression and sensitivity to cGMP mediated
vasodilatation, these data suggest that a decrease in Ang II induced
activation of the AT1 receptor regulates LZ+ MYPT1 expression,
possibly by decreasing p42/44 MAPK signaling. During the
activation of B and T lymphocytes, alternative mRNA splicing of
the cell surface marker CD44 has been demonstrated to depend on
activation of Raf1-MEK-p42/44 MAPK signaling, but not p38
MAPK [45], which suggests that p42/44 MAPK signaling could
Figure 3. The expression and activation of p38 MAPK does not
change following LAD ligation. Western blots with anti-phospho-
p38 MAPK antibody and anti-p38 MAPK antibody demonstrate that
both p38 MAPK and phospho-p38 MAPK are barely detectable in aortic
smooth muscle in control and rats following LAD ligation (CHF,
CHF+losartan). Both p38 MAPK and phosphorylated p38 MAPK are
detected in cultured rat SMCs. The Coomassie stained gel shows actin,
the loading control.
doi:10.1371/journal.pone.0005144.g003
Figure 4. Relative LZ+ MYPT1 expression falls following LAD
ligation, which is preserved with ARB. (A) Western blots
demonstrate that the relative expression of the LZ+ MYPT1 isoform
falls following LAD ligation, but is preserved at control levels in the rats
treated with losartan. The Coomassie stained gel shows actin, the
loading control. (B) Bar graph represents the relative expression of the
LZ+ MYPT1 isoform (given as LZ+ MYPT1/MYPT1) in control rats and
animals after LAD ligation. The relative expression of LZ+ MYPT1 in the
controls was set at 1. The data represent mean6SEM for control (n=9),
rats following LAD ligation treated with either vehicle (CHF, n=12) or
losartan (CHF+losartan, n=9), and control animals treated with losartan
(Control+losartan, n=4). The * indicated a significant difference
compared to controls, while the
‘ is a significant difference compared
to losartan treatment.
doi:10.1371/journal.pone.0005144.g004
MAPK Signaling during CHF
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evidence suggests that Tra2b is an important regulator of alternative
splicing of the 31 bp 39 exon (MYPT1 E23), which codes for the
presence or absence of the MYPT1 LZ [46]. These investigators
demonstrated that Tra2b binds to the MYPT1 E23 sequence and
transactivates splicing of MYPT1 E23 both in vitro and in vivo.
Although the pathway between activation of the AT1 receptor and
LZ+ MYPT1 expression has yet to be elucidated, the p42/44
MAPK signaling pathway has been demonstrated to have a role in
alternative mRNA splicing [45], and could regulate LZ+ MYPT1
expression, possibly by controlling the expression of Tra2b.
Our results demonstrate that Ang II stimulation of AT1
receptor both activates p42/44 MAPK signaling and decreases
the expression of the LZ+ MYPT1 isoform. Thus the ability of
ACE-inhibition and ARBs to counter this deleterious effect on the
vascular phenotype could explain their beneficial effect, compared
to other agents that decrease afterload, on morbidity and mortality
in the treatment of heart failure. Further, our data may suggest
that blocking the p42/44 MAPK cascade could preserve normal
vascular reactivity and reverse the vascular dysfunction associated
with heart failure.
Materials and Methods
Ethics Statement
All work was performed in accordance with the APS principles
for ethical treatment of animals, using a protocol approved by the
IACUC of the Mayo Medical School.
MI surgery
Myocardial infarction was induced by LAD ligation as
previously reported [22]. Briefly using a protocol approved by
the IACUC of the Mayo Medical School, adult male Sprague-
Dawley rats (Harlan,IN) weighing 300–400 g were anesthesized
with an intramuscular injection of a 5:1 mixture of ketamine
(100 mg/mL) and xylazine (100 mg/mL). After intubation, rats
were mechanically ventilated using a small animal ventilator
(model 683, Harvard). A left lateral thoracotomy was performed
along the 5
th intercostal space, followed by dissection of
pericardium to expose the heart. The left anterior descending
coronary artery (LAD) was visualized and ligated using 6-0 prolene
suture (Ethicon). After chest closure with running 3-0 vicryl suture
(Ethicon), the air in the chest cavity was evacuated, and the rats
were then placed in a warmed recovery chamber overnight.
Control animals underwent a sham procedure, where the only
difference was that the LAD was not ligated. Following surgery,
animals were divided into a vehicle treated or losartan treated
group. For the losartan group, rats were allowed to drink water
containing 50 mg/l losartan, ad libitum, which is approximately
3 mg/kg/day for 4 weeks.
Echocardiograms
Prior to imaging, animals were anesthetized with 2% isoflurane.
The anterior chest hair was removed, and the rats were placed in
supine position and the EKG was continuously monitored
[22,24,47]. The echocardiographic studies were performed using
the Vivid 7 ultrasound system (GE Medical Systems, Milwaukee,
Wis) and a 10S transducer (11.5 MHz) with high temporal and
spatial resolution. Grey scale images were recorded in the
parasternal long and short axis views. M-mode tracings were
obtained at the level of the papillary muscles at a speed of
200 mm/sec. Measurements were performed offline using the
EchoPAC PC software (GE Medical Systems, version 3.1.3).
Fractional shortening was obtained using the formula:
((LVIDd2LVIDs)/LVDd)6100 where LVIDd is the LV diameter
at end-diastole and LVIDs is the LV diameter at end-systole and
the LVEF was calculated as ((LV end-diastolic volume2LV end-
systolic volume)/(LV end-diastolic volume))6100%.
Western Blots
The aorta was dissected and cleaned of connective tissue, and
protein extracted in SDS sample buffer. The sample was resolved
by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using 8%
(29:1) gels for MYPT1 and 12% (29:1) gels for MAPK. The actin
band on Coomassie stained gels was used to normalize protein
loading. Following SDS-PAGE separation, protein bands were
transferred to a nitrocellulose membrane in buffer containing 16
NuPAGE transfer buffer, 20% methanol, and then blocked in 5%
nonfat dry milk with 16TBS including 0.05% (v/v) TWEEN for 1
hour. Antibodies used were a polyclonal anti-MYPT1 (Covance
F38.130, PRB-457C), a monoclonal anti-LZ+ MYPT1 isoform
[48], anti-p38 MAPK, anti-p42/44 MAPK, anti-phospho-p38
MAPK and anti-phospho-p42/44 MAPK (Cell Signaling #9212,
#9102, #9211S, #9101S, respectively). Alkaline phosphatase was
used to detect MYPT1, whereas enhanced chemiluminescence
(ECL) was used for the detection of MAPK, and the identified
protein bands were visualized using a Typhoon 9400 Variable
Mode Imager (Amersham Biosciences). Protein expression was
first normalized for the actin intensity on the corresponding
Coomassie stained SDS. Then, the relative activation of MAPK
was calculated as the normalized intensity of the band(s)
representing phospho-p38 MAPK or phospho-p42/44 MAPK
divided by the normalized intensity of the band corresponding
nonphosphorylated protein, and the level in the controls was set as
1. Similarly, the relative expression of the LZ+ MYPT1 isoform
was calculated as the intensity of the band(s) representing the LZ+
MYPT1 isoform divided by the intensity of the band(s)
representing total MYPT1, and the control level was set to 1.
Statistical Analysis
Data in the text are given as mean6SEM, and differences
between groups were determined using an ANOVA with
significance at the p,0.05 level.
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